In light of the opioid epidemic and evidence suggesting that cannabis may be opioid-sparing,
we are in a unique position to conduct a novel, high-impact study that would set the stage
for future RCTs examining the effects of a nonintoxicating and nonaddictive cannabinoid in an
orthopedic patient population. Epidiolex®, an oral cannabidiol (CBD) solution, is the first
ever cannabis-derived medication to be approved by the Food & Drug Administration. Our aim is
to conduct a pilot study using a placebo oral solution, 400mg and 800mg Epidiolex® to gather
data on its effects on patients undergoing bilateral total knee arthroplasty (BTKA). We will
be estimating whether Epidiolex® is associated with minimal opioid use and adequate
analgesia. We will also assess its tolerability, pharmacokinetics, and effects on
inflammatory markers in the perioperative setting.